Literature DB >> 27235014

Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes in mice.

Kanako Tsuboi1,2, Tomoka Hasegawa1, Tomomaya Yamamoto1, Muneteru Sasaki3, Hiromi Hongo1, Paulo Henrique Luiz de Freitas4, Tomohiro Shimizu5, Masahiko Takahata5, Kimimitsu Oda6, Toshimi Michigami7, Minqi Li8, Yoshimasa Kitagawa2, Norio Amizuka9.   

Abstract

In order to determine whether osteoclastic bone resorption is restarted after withdrawn of bisphosphonates, we conducted histological examinations on murine osteoclasts, osteoblasts and osteocytes after discontinuation of a daily regimen of alendronate (ALN) with a dosage of 1 mg/kg/day for 10 days. After drug discontinuation, metaphyseal trabecular number and bone volume remained unaltered for the first 4 days. Osteoclast number did not increase, while the number of apoptotic osteoclasts was elevated. On the other hand, tissue non-specific alkaline phosphatase-immunoreactive area was markedly reduced after ALN discontinuation. In addition, osteocytes showed an atrophic profile with empty lacunar areas during and after ALN treatment. Interestingly, as early as 36 h after a single ALN injection, osteocytes show signs of atrophy despite the presence of active osteoblasts. Structured illumination microscopy system showed shortening of osteocytic cytoplasmic processes after drug cessation, suggesting a possible morphological and functional disconnection between osteocytes and osteoblasts. Taken together, it appears that osteoclastic bone resorption is not resumed after ALN discontinuation; also, osteoblasts and osteocytes hardly seem to recover once they are inactivated and atrophied by ALN. In summary, it seems that one must pay more attention to the responses of osteoblasts and osteocytes, rather focusing on the resuming of osteoclastic bone resorption after the ALN discontinuation.

Entities:  

Keywords:  Bisphosphonates; Discontinuation; Osteoblast; Osteocyte

Mesh:

Substances:

Year:  2016        PMID: 27235014     DOI: 10.1007/s00418-016-1450-7

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  36 in total

1.  Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice.

Authors:  Naoko Sakagami; Norio Amizuka; Minqi Li; Kiichi Takeuchi; Masaaki Hoshino; Midori Nakamura; Kayoko Nozawa-Inoue; Nobuyuki Udagawa; Takeyasu Maeda
Journal:  Micron       Date:  2005-09-07       Impact factor: 2.251

2.  Alendronate disturbs vesicular trafficking in osteoclasts.

Authors:  A Alakangas; K Selander; M Mulari; J Halleen; P Lehenkari; J Mönkkönen; J Salo; Kalervo Väänänen
Journal:  Calcif Tissue Int       Date:  2001-12-21       Impact factor: 4.333

3.  Endocytic pathway from the basal plasma membrane to the ruffled border membrane in bone-resorbing osteoclasts.

Authors:  H Palokangas; M Mulari; H K Väänänen
Journal:  J Cell Sci       Date:  1997-08       Impact factor: 5.285

4.  High-dose alendronate uncouples osteoclast and osteoblast function: a study in a rat spine pseudarthrosis model.

Authors:  Andrew A Sama; Safdar N Khan; Elizabeth R Myers; Russel C Huang; Frank P Cammisa; Harvinder S Sandhu; Joseph M Lane
Journal:  Clin Orthop Relat Res       Date:  2004-08       Impact factor: 4.176

5.  Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.

Authors:  Midori Nakamura; Nobuyuki Udagawa; Sachiko Matsuura; Makio Mogi; Hiroshi Nakamura; Hiroshi Horiuchi; Naoto Saito; B Yukihiro Hiraoka; Yasuhiro Kobayashi; Kunio Takaoka; Hidehiro Ozawa; Hiroo Miyazawa; Naoyuki Takahashi
Journal:  Endocrinology       Date:  2003-09-18       Impact factor: 4.736

6.  Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis.

Authors:  D Amin; S A Cornell; S K Gustafson; S J Needle; J W Ullrich; G E Bilder; M H Perrone
Journal:  J Lipid Res       Date:  1992-11       Impact factor: 5.922

7.  Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.

Authors:  Robyn K Fuchs; Roger J Phipps; David B Burr
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

Review 8.  New insights into the molecular mechanisms of action of bisphosphonates.

Authors:  Michael J Rogers
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

9.  Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage.

Authors:  D D Bikle; E R Morey-Holton; S B Doty; P A Currier; S J Tanner; B P Halloran
Journal:  J Bone Miner Res       Date:  1994-11       Impact factor: 6.741

Review 10.  Histology of epiphyseal cartilage calcification and endochondral ossification.

Authors:  Norio Amizuka; Tomoka Hasegawa; Kimimitsu Oda; Paulo Henrique Luiz de Freitas; Kazuto Hoshi; Minqi Li; Hidehiro Ozawa
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01
View more
  8 in total

1.  Histochemical evidence of IGF2 mRNA-binding protein 2-mediated regulation of osteoclast function and adhesive ability.

Authors:  Hongrui Liu; Dongfang Li; Shanshan Liu; Zhaopeng Liu; Minqi Li
Journal:  Histochem Cell Biol       Date:  2018-01-10       Impact factor: 4.304

Review 2.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

Review 3.  Pathologic conditions of hard tissue: role of osteoclasts in osteolytic lesion.

Authors:  Riko Kitazawa; Ryuma Haraguchi; Mana Fukushima; Sohei Kitazawa
Journal:  Histochem Cell Biol       Date:  2018-01-22       Impact factor: 4.304

4.  Histomorphometric analysis of minimodeling in the vertebrae in postmenopausal patients treated with anti-osteoporotic agents.

Authors:  Tomohiro Hikata; Tomoka Hasegawa; Keisuke Horiuchi; Nobuyuki Fujita; Akio Iwanami; Kota Watanabe; Ken Ishii; Masaya Nakamura; Norio Amizuka; Morio Matsumoto
Journal:  Bone Rep       Date:  2016-10-13

5.  Bisphosphonate Modulation of the Gene Expression of Different Markers Involved in Osteoblast Physiology: Possible Implications in Bisphosphonate-Related Osteonecrosis of the Jaw.

Authors:  Francisco Javier Manzano-Moreno; Javier Ramos-Torrecillas; Lucia Melguizo-Rodríguez; Rebeca Illescas-Montes; Concepción Ruiz; Olga García-Martínez
Journal:  Int J Med Sci       Date:  2018-02-12       Impact factor: 3.738

Review 6.  Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives.

Authors:  Chenggui Zhang; Chunli Song
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

7.  Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy.

Authors:  Hiroaki Ishida; Hirotaka Komaba; Naoto Hamano; Hideyuki Yamato; Kaichiro Sawada; Takehiko Wada; Michio Nakamura; Masafumi Fukagawa
Journal:  J Bone Miner Metab       Date:  2020-03-05       Impact factor: 2.626

8.  The Effect of Alendronate on Osteoclastogenesis in Different Combinations of M-CSF and RANKL Growth Factors.

Authors:  Věra Hedvičáková; Radmila Žižková; Matěj Buzgo; Michala Rampichová; Eva Filová
Journal:  Biomolecules       Date:  2021-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.